.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a median consequence of 11 months, patients along with metastatic stomach lumps who acquired biomarker-matched therapies based upon flowing growth DNA profiling revealed a better professional advantage than those acquiring unrivaled treatment.